Elicio Therapeutics Q3 2026 net loss narrows 21% to $7.98 million
ELTX•Elicio Therapeutics’ third-quarter 2026 net loss narrowed 21% year over year to $7.98 million. It had $30.9 million in cash and cash equivalents at September 30 and expects funding into the second quarter of 2027.
1. Quarterly results and trials
Elicio Therapeutics’ third-quarter 2026 net loss narrowed 21% year over year to $7.98 million, and cash and cash equivalents totaled $30.9 million at September 30, with operations expected to be funded into the second quarter of 2027. AMPLIFY-7P missed its primary disease-free survival endpoint, while subgroup findings inform a planned Phase 3 study in adjuvant pancreatic cancer; a Phase 1 metastatic pancreatic cancer study combining camupepimut with daraxonrasib, with or without nivolumab, is targeted to begin in Q4 2026.
